Pharmaceutical leader Moderna has initiated an experimental trial in the United Kingdom for a cancer treatment leveraging mRNA technology, akin to that used in its COVID-19 vaccine. This new venture is focused on utilizing mRNA to develop a cancer vaccine, with the trial being conducted at the Imperial College Healthcare NHS Trust.
This cutting-edge treatment, identified as mRNA-4359, is undergoing a phase 1/2 trial, aiming to determine its efficacy and safety in treating various cancers such as melanoma and lung cancer, among others. The vaccine is designed to educate the immune system to recognize and combat cancer cells by exposing it to common cancer markers through mRNA technology.
Imperial College London elaborated on the technique, stating, “Whereas the COVID-19 vaccines trained immune cells using mRNA of a protein on the outside of the virus, these experimental mRNA cancer immunotherapies incorporate mRNA of common marker proteins found in tumors.”
An 81-year-old participant from Surrey, battling malignant melanoma unresponsive to conventional treatments, has been reported as the first individual to receive this innovative treatment. He shared, “I had a different immunotherapy, I had radiotherapy – the only thing I didn’t have was chemotherapy. So, the options were either do nothing and wait, or get involved and do something.”
Moderna’s mRNA-4359 will be tested both independently and in combination with pembrolizumab (Keytruda), a recognized cancer immunotherapy drug. This initiative is part of Moderna’s broader exploration into mRNA technology for addressing various diseases, including influenza, HIV, and Zika virus.
Despite the novel approach, skepticism exists around Moderna’s ventures, especially considering its history prior to the COVID-19 vaccine. Critics argue that Moderna had not successfully developed a market-approved drug before. Concerns about the COVID-19 vaccine’s effectiveness and safety have also been raised, with some individuals suggesting it led to serious health issues. A commenter critiqued, “Moderna’s ‘safe and effective’ COVID vaccine did not prevent a person from being infected by the COVID virus, nor did it prevent the transmission of the virus COVID to others.”
Another commented on the company’s background, “Moderna was a failing cancer-curing company prior to the con. They never cured a single patient in 10 years.” These sentiments underscore the controversy surrounding Moderna’s new foray into cancer treatment with mRNA technology.
Sources for this article include commentary from 100PercentFedUp.com and NaturalNews.com, offering a blend of scientific updates and public skepticism surrounding the development of mRNA-based treatments by Moderna.
